Richi Alberti, PatriciaAlonso Gisbert, OriolMartín, María DoloresGonzález Hombrado, LauraAndreu Vázquez, CristinaThuissard Vasallo, Israel JohnCobo Ibáñez, María TatianaIllera Martín, ÓscarSteiner, MartinaMuñoz Fernández, SantiagoEt al.2021-03-102021-03-102020Richi, P., Alonso, O., Martín, M. D., González-Hombrado, L., Navío, T., Salido, M., Llorente, J., Andreu-Vázquez, C., García-Fernández, C., Jiménez-Díaz, A., Lojo, L., Cebrián, L., Thuissard-Vasallo, I., Martínez de Aramayona, M. J., Cobo, T., García-Castro, M., Castro, P., Fernández-Castro, M., Illera, Ó., Steiner, M., … Muñoz-Fernández, S. (2020). Evaluation of the immune response to hepatitis B vaccine in patients on biological therapy: Results of the RIER cohort study. Clinical Rheumatology, 39(9), 2751–2756. https://doi.org/10.1007/s10067-020-05042-21434-99490770-3198http://hdl.handle.net/11268/9902To evaluate the response to hepatitis B virus (HBV) vaccine in patients on biological therapy. Adults with autoimmune inflammatory diseases on biological therapy such as anti-TNFα, rituximab, tocilizumab, abatacept, or anakinra were included. Hepatitis B surface antibody (anti-HBs) was measured by ELISA before and after vaccination. Seroconversion was considered when an anti-HBs titer > 10 mIU/mL was achieved. The effect of treatment on the immunoprotective state was studied. The response was compared with that obtained in patients on synthetic disease modifying anti-rheumatic drugs (DMARDs) and healthy controls. A total of 187 patients on biologicals, 48 on synthetic DMARDs, and 49 on healthy controls were analyzed. More than 80% of patients on biologics responded to the vaccine but required more boosters and second vaccine series. Patients who achieved seroconversion were younger than those who did not (47.10 ± 12.99 vs. 53.18 ± 10.54 years, p = 0.012). Being on etanercept or golimumab was associated with seroconversion, while being on rituximab was not. Seroconversion was achieved in 93.75% of patients on synthetic DMARDs and 97.96% of healthy controls. The seroconversion rate in the biologics group was lower than in the synthetic DMARD group (p = 0.043) and tended to be lower than in the healthy group (p = 0.056). In patients on biological therapy, a high rate of HBV vaccine response can be achieved when a complete vaccination schedule is administered. Vaccination while not on biological agents reduces the requirement for boosters and revaccination.engHepatitis BTerapia biológicajournal article10.1007/s10067-020-05042-2restricted accessSistema endocrinoEnfermedadVacunación